BioCrine
  • Home
  • About Us
    • Company and People
    • Board of Directors
    • Management
    • Partners
  • Research Programs
    • Pipeline overview
    • Diabetes as a disease
    • Biocrine drug discovery strategy
    • Serum factor apoCIII
    • Insulin receptor isoforms
    • Calcium channels
    • Inositol pyrophosphates
  • InSight Technology
    • What is it?
    • How does it work?
    • Where can it be used?
  • News
  • Contact
Home » News » Publication » Transplantation into the eye can cure diabetes

Transplantation into the eye can cure diabetes

 

 

 

 

Insulin shots for patients with type 1 diabetes can become history. A novel site to transplant donor islet of Langerhans may give a chance to cure patients’ own failing insulin production. When transplanted into the anterior chamber of the eye of a diabetic monkey, pancreatic islets survive and produce insulin, reducing the concentration of glucose in the blood. The results are published in Diabetologia, March 2011.

Patients with type 1 diabetes suffer from lack of insulin, as the majority of pancreatic beta cells in the islets of Langerhans are destroyed. One of the ways to solve this problem is to provide the patients with functioning donor beta cells. A limitation of the method is patient’s own immune system. It will react to the transplanted cells the same way as to any other foreign material – the cells will be stepwise destroyed.

Islet transplantation surgeons around the world try to find sites more suitable for islet survival. Researchers at Biocrine have recently suggested that the anterior chamber of the eye may constitute such a site. This part of the eye has a unique immune privilege. It has also an advantage of being easily accessible for local application of immunosuppressive drugs. These two factors may lead to better survival of the transplanted islets and less problems for the patient.

A successful transplantation of pancreatic islets into the anterior chamber of a diabetic baboon eye has recently been carried out in the Miller School of Medicine at the University of Miami by scientists in Professor Berggren’s group at the Diabetes Research Institute in collaboration with scientists at the Bascom Palmer Eye Institute. Following transplantation, requirements for external insulin supply became lower, while internal insulin production became higher and glucose metabolism more stable.

Only after a few days, the islets got vascularized, thus receiving necessary blood supply. Moreover, the animal did not get any ophthalmological complications, such as loss of sight, inflammation, high eye pressure or discomfort.

The safety, simplicity, and effectiveness of transplanting the islets of Langerhans into the anterior chamber of the eye bare a promise to improve the situation for patients with type 1 diabetes.

Read more:
The anterior chamber of the eye as a clinical transplantation site for the treatment of diabetes: a study in a baboon model of diabetes. Perez VL. Diabetologia. 2011 May;54(5):1121-6

December 4, 2012 Catharina Rahm

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Categories

Recent posts

  • Professor Berggren’s research publications
    Professor Berggren’s research publications February 6, 2025
  • Årsstämma 17 juni 2024
    Årsstämma 17 juni 2024 June 2, 2024
  • Researchers use the eye as a window to study liver health
    Researchers use the eye as a window to study liver health February 8, 2024
  • ERC Proof of Concept to Professor Per-Olof Berggren
    ERC Proof of Concept to Professor Per-Olof Berggren February 7, 2024
  • The anterior chamber of the eye as a servant to medical research in translation
    The anterior chamber of the eye as a servant to medical research in translation February 7, 2024
  • Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize
    Lisa Juntti-Berggren receives the Swedish Society of Medicine’s Jubilee Prize February 7, 2024
  • Eye implant may be used to treat diabetes
    Eye implant may be used to treat diabetes February 7, 2024
  • Årsstämma 16 juni 2023
    Årsstämma 16 juni 2023 May 29, 2023
  • New strategy to preserve insulin-producing cells in diabetes
    New strategy to preserve insulin-producing cells in diabetes August 19, 2022
  • Kallelse till årsstämma 27 juni 2022
    Kallelse till årsstämma 27 juni 2022 June 6, 2022

Biocrine AB

Box 3073

169 03 Solna, Sweden

Contact Us

info at biocrine.se

www.biocrine.com

Copyright © 2012 Biocrine AB. All Rights Reserved